Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.57 |
| ▸ | CES1 | P23141 | 4/20 | 0.57 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.55 |
| ▸ | PPARG | P37231 | 7/20 | 0.55 |
| ▸ | PPARD | Q03181 | 7/20 | 0.55 |
| ▸ | PPARA | Q07869 | 7/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | FABP4 | P15090 | 2/20 | 0.55 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.55 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23892 | 1.00 | CES2 (0.57) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL368594 | 1.00 | — | — | |
| SCHEMBL4814086 | 1.00 | CES2 (0.57) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL7749105 | 1.00 | CES2 (0.57) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL7743611 | 1.00 | CES2 (0.57) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL5430307 | 1.00 | CES2 (0.57) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL3777730 | 1.00 | CES2 (0.57) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL5340694 | 1.00 | CES2 (0.57) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL11320726 | 1.00 | CES2 (0.57) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL372778 | 1.00 | CES2 (0.57) | CES2CES1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-20250345299-A1 | COMBINATION AND COMPOSITION COMPRISING NICOTINIC ACID OR DERIVATIVE THEREOF AND FATTY ACID OR DERIVATIVE THEREOF | T OMEGA AS (NO) | 2025-11-13 | — | — | US | claimed |
| CN-113939288-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-04-25 | — | — | CN | claimed |
| EP-4522141-A1 | COMBINATION AND COMPOSITION COMPRISING NICOTINIC ACID OR DERIVATIVE THEREOF AND FATTY ACID OR DERIVATIVE THEREOF | T Omega AS (NO) | 2025-03-19 | — | — | EP | claimed |
| CN-119522096-A | Combinations and compositions comprising niacin or derivatives thereof and fatty acids or derivatives thereof | T欧米伽股份有限公司 | 2025-02-25 | — | — | CN | claimed |
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | claimed |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-12 | — | — | US | claimed |
| CN-117451817-A | High-sensitivity glucose detection device and preparation method thereof | 清华大学深圳国际研究生院 | 2024-01-26 | — | — | CN | claimed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | claimed |
| EP-1232750-A1 | Non-beta-oxidizable fatty acid analogues and their use for reduction of growth of cancer cells | Berge, Rolf (NO) | 2002-08-21 | — | — | EP | claimed |
| WO-2002043728-A1 | FATTY ACID ANALOGUES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISORDERS | THIA MEDICA AS (NO) | 2002-06-06 | — | — | WO | claimed |
| WO-2002026218-A2 | FATTY ACID ANALOGUES FOR THE TREATMENT OF PROLIFERATIVE SKIN DISORDERS | THIA MEDICA AS (NO) | 2002-04-04 | — | — | WO | claimed |
| EP-1180013-A1 | LOCAL DRUG DELIVERY | BIOCOMPATIBLES LTD. (GB) | 2002-02-20 | — | — | EP | claimed |
| WO-2002003983-A1 | FATTY ACID ANALOGUES FOR THE TREATMENT OF CANCER | THIA MEDICA AS (NO) | 2002-01-17 | — | — | WO | claimed |
| WO-2001001957-A1 | LOCAL DRUG DELIVERY | BIOCOMPATIBLES LIMITED (GB) | 2001-01-11 | — | — | WO | claimed |
| US-6046237-A | ADMINISTERING TO A MAMMAL AN EFFECTIVE AMOUNT OF NON-BETA-OXIDIZABLE FATTY ACID CONTAINING SELENIUM ATOM IN HYDROCARBON CHAIN FOR THE TREATMENT OF HYPERLIPIDEMIA AND ANTHEROGENIC CONDITIONS | BERGE ROLF (NO) | 2000-04-04 | — | — | US | claimed |
| WO-1999058120-A1 | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS | BERGE ROLF (NO) | 1999-11-18 | — | — | WO | claimed |
| EP-0840604-A1 | NON-BETA-OXIDIZABLE FATTY ACID ANALOGUES, THEIR USES AS THERAPEUTIC ACTIVE MEDICAMENTS, AND PREPARATION THEREOF | Berge, Rolf (NO) | 1998-05-13 | — | — | EP | claimed |
| WO-1997003663-A1 | NON-β-OXIDIZABLE FATTY ACID ANALOGUES, THEIR USES AS THERAPEUTIC ACTIVE MEDICAMENTS, AND PREPARATION THEREOF | BERGE ROLF (NO) | 1997-02-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | CES2 2511/4885CES1 1444/4885GPR84 74/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | CES2 1300/4885CES1 750/4885GPR84 116/4885 |
| US-20250345299-A1 | COMBINATION AND COMPOSITION COMPRISING NICOTINIC ACID OR DERIVATIVE THEREOF AND FATTY ACID OR DERIVATIVE THEREOF | HADHA, HAGH, HADHB | CES2 3215/4885CES1 1263/4885GPR84 1033/4885 |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | CES2 2511/4885CES1 1444/4885GPR84 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.